Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis.

ABSTRACT: Psoriasis is a chronic inflammatory skin pathology of autoimmune origin and unknown etiology. There are various therapies for treating it, including a wide range of biopharmaceuticals indicated in moderate-to-severe psoriasis. Depending on their therapeutic target, they are classified as tumor necrosis factor inhibitors (anti-TNF) or cytokine inhibitors (interleukin-12, 23, and 17 antagonists). Although they have proved effective and safe, in clinical practice, many patients show a short- and long-term suboptimal response and even varying degrees of toxicity. This variability in response may be influenced by genetic factors, such as polymorphisms in the genes involved in the pathological environment, metabolism or mechanism of action of the drug that could affect the effectiveness and toxi

SUBMITTER: Membrive Jimenez C 

PROVIDER: S-EPMC8069496 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature